General Biotechnology

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a footnote—it’s a strategic playbook. And the most important part isn’t the headlines about approvals or launches. It’s the patent pipeline behind them: the quiet, methodical work that determines who can compete, …

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

General Biotechnology

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors

The drug patent clock is ticking—most IP teams are forecasting it with the wrong instrument.
In pharma, timing isn’t just strategy—it’s value. A few months can decide whether a blockbuster stays protected, whether a generic launch triggers price erosio…

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors Read Post »

Biotechblog
Scroll to Top